Combined Immunotherapy and Hybrid Dose-Fraction Radiotherapy for Driver-Negative Metastatic NSCLC: A Phase II Trial with Parallel Preclinical Studies.
Ziye Li, Xiaoyang Li, Xiaoying Wei et al.
✦ AI-curated · Sources linked
In 30 seconds
This single-arm, multicenter phase II trial evaluated hybrid dose-fraction radiotherapy added during first-line chemoimmunotherapy maintenance in 83 patients with stage IV driver-negative metastatic NSCLC. Radiotherapy used SABR for targetable lesions and low-dose radiotherapy for other sites; patients restaged to stage III received short-course hypofractionated radiotherapy to residual lesions. The primary endpoint was met: the 1-year progression-free survival rate was 54.2%, with median PFS of 16.1 months (95% CI 11.4 to 19.2 months). The regimen was reported as well tolerated. Parallel murine studies examined immune mechanisms.
Key findings
- The 1-year PFS rate was 54.2%; median PFS was 16.1 months (95% CI 11.4 to 19.2 months).
- The 1-year OS rate was 83.1%; median OS was 29.3 months (95% CI 21.9 months to not reached).
- Treatment was reported as well tolerated, and peripheral profiling showed posttreatment expansion of cytotoxic CD8+ T cells and NK cells.
- In the murine model, combined treatment promoted distinct CD8+ T-cell and NK-cell roles across radiotherapy sites and suppressed Spp1+ macrophages.
Why it matters
The study explores whether radiotherapy with different dose-fractionation strategies can complement chemoimmunotherapy in metastatic driver-negative NSCLC, where clinical benefit remains limited. Its clinical outcomes and immune findings provide a rationale for further evaluation of this approach, while the single-arm design means the observed outcomes cannot establish benefit over chemoimmunotherapy alone.
What to keep in mind
The clinical trial was single-arm, so it cannot determine whether outcomes were improved by adding Hybrid-RT compared with chemoimmunotherapy alone.